62 completed, 9 unknown, 4 not yet recruiting, 3 recruiting. 40 Phase 3, 16 Phase 4, 13 Phase 2, 3 Phase 1, 2 Not applicable.
Follow Rubivirus Infections: new trials by email Literature Review of Rubivirus Infections trials Research Report on Rubivirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine - Measles, Mumps | Phase 3 | Not yet recruiting | GlaxoSmithKline | 1860 | 2026-08-11 | 2026-08-03 |
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age MMRVNS, MMRV - Measles, Measles-Mumps-Rubella+Chickenpox Vaccine | Phase 3 | Recruiting | GlaxoSmithKline | 1209 | 2026-05-11 | 2026-07-08 |
| the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines Polio, Measles | Not yet recruiting | China National Biotec Group Company Limited | 600 | 2026-01-30 | 2026-01-14 | |
| Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective Dengue, Chikungunya | Recruiting | Institut Pasteur du Cambodge | 10000 | 2025-12-18 | 2026-01-22 | |
| Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients Commercial measles, mumps, and rubella (MMR) vaccine - Heart Transplant Infection Prevention | Phase 4 | Recruiting | Children's Mercy Hospital Kansas City | 60 | 2025-09-11 | 2026-09-24 |
| Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections Exanthema, Dengue Fever | Not yet recruiting | Hospital Israelita Albert Einstein | 830 | 2025-09-01 | 2025-08-08 | |
| Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months Measles-Rubella vaccine (Live) I.P. (Freeze Dried) of M/s. Zydus Lifesciences Ltd, Yellow fever Vaccine (WHO prequalified) - Measles, Rubella | Phase 3 | Not yet recruiting | International Centre for Diarrhoeal Disease Research, Bangladesh | 1530 | 2025-04-01 | 2025-02-07 |
| Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months SIBP MMR Vaccine, GSK MMR Vaccine (PRIORIX), Yellow Fever Vaccine (Stamaril) - Measles-Mumps-Rubella | Phase 3 | Completed | Shanghai Institute Of Biological Products | 1200 | 2024-06-28 | 2026-01-08 |
| Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR) Vero cell-drived inactive Japanese encephalitis vaccine, Measles-Mumps-Rubella Vaccine - Japanese Encephalitis, Measles | Phase 4 | Completed | Liaoning Chengda Biotechnology CO., LTD | 408 | 2024-03-02 | 2025-08-28 |
| Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination MMR booster vaccination (as M-M-R-VaxPro) - Mumps, Measles | Phase 3 | Unknown | University of Zurich | 200 | 2023-12-01 | 2024-01-08 |
| Co-administration Study of OCV, TCV and MR Oral Cholera Vaccine (OCV), Typhoid Conjugate Vaccine (TCV), Measles and Rubella (MR) - Typhoid, Cholera | Phase 3 | Unknown | International Centre for Diarrhoeal Disease Research, Bangladesh | 2117 | 2023-10-14 | 2023-10-13 |
| Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine, Inactivated SARS-CoV-2 vaccine coadministered with MMR, Inactivated SARS-CoV-2 vaccine administered alone - SARS-CoV-2 Infection, Varicella | Phase 4 | Unknown | Shanghai Municipal Center for Disease Control and Prevention | 540 | 2023-08-01 | 2023-07-19 |
| A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine - Measles; Mumps; Rubella; Chickenpox, Measles | Phase 2 | Completed | GlaxoSmithKline | 801 | 2022-12-14 | 2025-06-22 |
| The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine HPV+MMR（0d），HPV（6m）, HPV（0d），HPV（6m），MMR（7m）, MMR（0d），HPV（1m），HPV（7m） - Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18 | Phase 4 | Unknown | Zhejiang Provincial Center for Disease Control and Prevention | 300 | 2021-08-25 | 2022-03-29 |
| Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial Measles Rubella Vaccine (MRV-SC), MRV-MNP, PLA-MNP - Measles, Rubella | Phase 1 / Phase 2 | Completed | Micron Biomedical, Inc | 281 | 2021-05-19 | 2023-03-29 |
| Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study) Measles-Rubella vaccine Bio Farma, MR Vaccine SII - Congenital Rubella Infection, Measles | Phase 2 / Phase 3 | Completed | PT Bio Farma | 540 | 2019-09-03 | 2019-12-04 |
| Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella Measles and Rubella vaccine, Measles, Mumps and Rubella vaccine - Rubella, Measles | Phase 2 / Phase 3 | Completed | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 432 | 2018-11-20 | 2020-08-13 |
| Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age Measles-rubella (MR) vaccine at 6 months of age, Measles-rubella (MR) vaccine at 9 months of age - Measles, Rubella | Phase 4 | Completed | Centers for Disease Control and Prevention | 637 | 2017-03-09 | 2025-07-16 |
| Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Live attenuated SA 14-14-2 Japanese Encephalitis vaccine, Measles, mumps, rubella vaccine - Encephalitis, Japanese, Measles | Phase 4 | Completed | PATH | 628 | 2016-10-13 | 2020-10-14 |
| Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Measles, mumps and rubella Combined Vaccine, Live - Measles, Mumps | Phase 4 | Completed | Centers for Disease Control and Prevention, China | 873 | 2016-03-01 | 2017-05-19 |
Showing 20 of 82. Sign in to see all of them.
Rubella (82) · Measles (81) · Mumps (69) · Chickenpox (44) · Encephalitis, Japanese (5) · Haemophilus Infections (5) · Hepatitis A (4) · Tetanus (4) · Meningitis, Meningococcal (3) · Poliomyelitis (3) · Whooping Cough (3) · Chikungunya Fever (2) · Dengue (2) · Diphtheria (2) · Giardiasis (2)
Infections (82) · RNA Virus Infections (82) · Togaviridae Infections (82) · Virus Diseases (82) · Mononegavirales Infections (81) · Morbillivirus Infections (81) · Paramyxoviridae Infections (81) · Mouth Diseases (69) · Parotid Diseases (69) · Parotitis (69) · Rubulavirus Infections (69) · Salivary Gland Diseases (69) · Stomatognathic Diseases (69) · DNA Virus Infections (46)
measles, mumps, rubella, varicella vaccine (21) · Measles-Mumps-Rubella Vaccine (16) · Chickenpox Vaccine (9) · Hepatitis A Vaccines (7) · Rubella Vaccine (7) · Heptavalent Pneumococcal Conjugate Vaccine (4) · Vaccines (4) · 13-valent pneumococcal vaccine (3) · Meningococcal Vaccines (3) · Vaccines, Attenuated (3) · CRM197 (non-toxic variant of diphtheria toxin) (2) · Priorix-Tetra vaccine (2) · Yellow Fever Vaccine (2) · Adenosine Monophosphate (1) · Aging (1)
GlaxoSmithKline (22) · Merck Sharp & Dohme LLC (18) · Sanofi Pasteur, a Sanofi Company (5) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (5) · Centers for Disease Control and Prevention, China (2) · International Centre for Diarrhoeal Disease Research, Bangladesh (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Takeda (2) · Assaf-Harofeh Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · Centers for Disease Control and Prevention (1) · Children's Mercy Hospital Kansas City (1) · China National Biotec Group Company Limited (1) · Hospital Israelita Albert Einstein (1) · Institut Pasteur du Cambodge (1)
United States (20) · Germany (8) · Puerto Rico (7) · China (6) · Italy (6) · Brazil (5) · Finland (5) · Taiwan (5) · France (4) · Estonia (3) · Bangladesh (2) · Canada (2) · Spain (2) · Switzerland (2) · Thailand (2)
Amanda Dempsey, MD, PhD, MPH (1) · Anne Fiquet, MD (1) · Carl T. D'Angio, MD (1) · Claude Flamand, Ph.D. (1) · Ed Clarke, MD (1) · Eliane Matos Santos (1) · Eran Kozer (1) · Eva Netterlid (1) · Huanyu Wang (1) · Huaqing Wang, MD, PhD (1)
PMID 16094218, PMID 16452343, PMID 16567978, PMID 16804432, PMID 17332177, PMID 17502347, PMID 19305145, PMID 19366435, PMID 20955461, PMID 22123890, PMID 22406278, PMID 22772170, PMID 25765966, PMID 26362659, PMID 27149048, PMID 27423382, PMID 28481690, PMID 29902133, PMID 30481110, PMID 30833160, PMID 31481612, PMID 36104719, PMID 40179934, PMID 41276263
2025 (2), 2014 (1)